Hunter Associates Investment Management’s Charles River Laboratories CRL Stock Holding History

Hunter Associates Investment Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,552	Closed	-$331K	–	261
2022 Q4	$331K	Buy	1,552 +137	+10%	+$29.9K	0.08%	167
2022 Q3	$274K	Buy	1,415 +72	+5%	+$15.5K	0.07%	179
2022 Q2	$279K	Buy	+1,343	New	+$328K	0.07%	177
2021 Q2	–	Sell	-1,370	Closed	-$397K	–	152
2021 Q1	$397K	Sell	1,370 -55	-4%	-$15.3K	0.09%	145
2020 Q4	$356K	Sell	1,425 -88	-6%	-$21K	0.09%	137
2020 Q3	$343K	Sell	1,513 -25	-2%	-$5.19K	0.1%	133
2020 Q2	$268K	Buy	+1,538	New	+$245K	0.08%	140

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Hunter Associates Investment Management's CRL Position: Q1 2023 in Review

Hunter Associates Investment Management sold out of Charles River Laboratories (CRL) in Q1 2023, closing a stake of 1,552 shares — an estimated $331K sold.

Hunter Associates Investment Management first reported a position in CRL in Q2 2020 and held it in 7 quarters. The position peaked at $397K in Q1 2021. 620 funds tracked by Wall St. Rank hold CRL as of Q1 2023.

Hunter Associates Investment Management reported no remaining Charles River Laboratories position as of Q1 2023 after selling out during the quarter.
Hunter Associates Investment Management sold 1,552 Charles River Laboratories shares in Q1 2023, an estimated $331K.
Hunter Associates Investment Management first reported a position in Charles River Laboratories in Q2 2020 and held it in 7 quarters.
Hunter Associates Investment Management's Charles River Laboratories position peaked at $397K in Q1 2021.
620 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2023.

Based on Hunter Associates Investment Management's 13F filing for Q1 2023, filed 2 May 2023.